organization · Reporting owner
PURA VIDA INVESTMENTS, LLC
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Greenlane Holdings, Inc.
Report date December 31, 2019 · Filed February 14, 2020
Jointly reported with Kamen Efrem
Section 16 reporting ended · disclosed 2020-02-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common Stock, par value $0.01SEC Table I · non-derivative | IndirectBy Pura Vida Investments | 549,017 |
Reported balance
After 2019-09-19 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-09-19 · Purchase · Acquired 35,000 · Balance 549,017 F1: Shares reported herein may be held by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida Pro Special Opportunity Master Fund, Ltd. (the "Pura Vida Pro Fund"), or certain separately managed accounts (the "Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager to the Pura Vida Master Fund and the Accounts. Pura Vida Pro, LLC ("PVP") serves as the investment manager to the Pura Vida Pro Fund. PVP is a relying adviser of PVI. Efrem Kamen serves as the Managing Member of both PVI and PVP. F3: This transaction was not previously reported due to the Adviser's inability to receive EDGAR access codes for one of its reporting persons. The filing deadline passed and the Adviser elected to report the transaction in a Form 5 filing. F2: The securities reported herein may be deemed beneficially owned by each of: (i) PVI, which is deemed the beneficial owner of shares held by the Pura Vida Master Fund, the Pura Vida Pro Fund, and the Accounts (collectively, the "Client Accounts") in its capacity as investment manager on behalf of itself and PVP as its relying advisor, and (ii) Efrem Kamen who serves as the Managing Member of both PVI and PVP. Mr. Kamen exercises voting and dispositive control over the securities and is therefore deemed to be a beneficial owner of securities owned or controlled by PVI. Each of PVI and Mr. Kamen disclaim beneficial ownership of the reported securities held by the Client Accounts, except to the extent of its or his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares reported herein may be held by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida Pro Special Opportunity Master Fund, Ltd. (the "Pura Vida Pro Fund"), or certain separately managed accounts (the "Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager to the Pura Vida Master Fund and the Accounts. Pura Vida Pro, LLC ("PVP") serves as the investment manager to the Pura Vida Pro Fund. PVP is a relying adviser of PVI. Efrem Kamen serves as the Managing Member of both PVI and PVP.
F2: The securities reported herein may be deemed beneficially owned by each of: (i) PVI, which is deemed the beneficial owner of shares held by the Pura Vida Master Fund, the Pura Vida Pro Fund, and the Accounts (collectively, the "Client Accounts") in its capacity as investment manager on behalf of itself and PVP as its relying advisor, and (ii) Efrem Kamen who serves as the Managing Member of both PVI and PVP. Mr. Kamen exercises voting and dispositive control over the securities and is therefore deemed to be a beneficial owner of securities owned or controlled by PVI. Each of PVI and Mr. Kamen disclaim beneficial ownership of the reported securities held by the Client Accounts, except to the extent of its or his pecuniary interest therein.
F3: This transaction was not previously reported due to the Adviser's inability to receive EDGAR access codes for one of its reporting persons. The filing deadline passed and the Adviser elected to report the transaction in a Form 5 filing.
Insight Molecular Diagnostics Inc.
Report date April 14, 2023 · Filed April 18, 2023
Jointly reported with Kamen Efrem
Section 16 reporting ended · disclosed 2023-04-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrant to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.53 · Expires 2027-04-19 | IndirectBy the Managed Accounts | 517,245 |
Reported balance
Holding disclosure · report date 2023-04-14 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance 517,245 F1: As of the reporting date, the Warrants are subject to an ownership blocker provision that prevents the Reporting Persons from exercising the Warrants if they would have voting and dispositive power for more than 9.99% of the common stock outstanding following such exercise. F2: Securities reported herein are owned by Pura Vida Master Fund, Ltd., Pura Vida X Fund LP, and Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust") and certain separately managed account(s) (the "Managed Accounts" and collectively, the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. |
| Warrant to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.53 · Expires 2027-04-19 | IndirectBy Pura Vida Master Fund, Ltd. | 832,949 |
Reported balance
Holding disclosure · report date 2023-04-14 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 832,949 F1: As of the reporting date, the Warrants are subject to an ownership blocker provision that prevents the Reporting Persons from exercising the Warrants if they would have voting and dispositive power for more than 9.99% of the common stock outstanding following such exercise. F2: Securities reported herein are owned by Pura Vida Master Fund, Ltd., Pura Vida X Fund LP, and Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust") and certain separately managed account(s) (the "Managed Accounts" and collectively, the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. |
| Warrant to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.53 · Expires 2027-04-19 | IndirectBy Pura Vida X Fund LP | 383,976 |
Reported balance
Holding disclosure · report date 2023-04-14 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 383,976 F1: As of the reporting date, the Warrants are subject to an ownership blocker provision that prevents the Reporting Persons from exercising the Warrants if they would have voting and dispositive power for more than 9.99% of the common stock outstanding following such exercise. F2: Securities reported herein are owned by Pura Vida Master Fund, Ltd., Pura Vida X Fund LP, and Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust") and certain separately managed account(s) (the "Managed Accounts" and collectively, the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. |
| Warrant to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.53 · Expires 2027-04-19 | IndirectBy the Retirement Trust | 690,719 |
Reported balance
Holding disclosure · report date 2023-04-14 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 690,719 F1: As of the reporting date, the Warrants are subject to an ownership blocker provision that prevents the Reporting Persons from exercising the Warrants if they would have voting and dispositive power for more than 9.99% of the common stock outstanding following such exercise. F2: Securities reported herein are owned by Pura Vida Master Fund, Ltd., Pura Vida X Fund LP, and Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust") and certain separately managed account(s) (the "Managed Accounts" and collectively, the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: As of the reporting date, the Warrants are subject to an ownership blocker provision that prevents the Reporting Persons from exercising the Warrants if they would have voting and dispositive power for more than 9.99% of the common stock outstanding following such exercise.
F2: Securities reported herein are owned by Pura Vida Master Fund, Ltd., Pura Vida X Fund LP, and Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust") and certain separately managed account(s) (the "Managed Accounts" and collectively, the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI.
F3: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any.
MedMen Enterprises, Inc.
Report date August 17, 2021 · Filed April 29, 2022
Jointly reported with Pura Vida Master Fund, LTD, Kamen Efrem
Section 16 reporting ended · disclosed 2022-04-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Senior Secured Convertible NoteSEC Table II · derivative / convertible security · Conversion / exercise price $0.17 · Expires 2028-08-17 | IndirectBy Pura Vida Master Fund, LTD. | Not disclosed |
Reported balance
After 2021-08-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-08-17 · Other · Disposed Not disclosed · Balance Not disclosed F1: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2: Currently exercisable. F4: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. |
| Senior Secured Convertible NoteSEC Table II · derivative / convertible security · Conversion / exercise price $0.15 · Expires 2028-08-17 | IndirectBy Pura Vida Master Fund, LTD. | Not disclosed |
Reported balance
After 2021-08-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-08-17 · Other · Disposed Not disclosed · Balance Not disclosed F1: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2: Currently exercisable. F4: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. |
| Senior Secured Convertible NoteSEC Table II · derivative / convertible security · Conversion / exercise price $0.34 · Expires 2028-08-17 | IndirectBy Pura Vida Master Fund, LTD. | Not disclosed |
Reported balance
After 2021-08-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-08-17 · Other · Disposed Not disclosed · Balance Not disclosed F1: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2: Currently exercisable. F4: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. |
| Senior Secured Convertible NoteSEC Table II · derivative / convertible security · Conversion / exercise price $0.28 · Expires 2028-08-17 | IndirectBy Pura Vida Master Fund, LTD. | Not disclosed |
Reported balance
After 2021-08-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-08-17 · Other · Disposed Not disclosed · Balance Not disclosed F1: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2: Currently exercisable. F4: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. |
| Senior Secured Convertible NoteSEC Table II · derivative / convertible security · Conversion / exercise price $0.17 · Expires 2028-08-17 | IndirectBy Pura Vida Pro Special Opportunity Master Fund, LTD. | Not disclosed |
Reported balance
After 2021-08-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-08-17 · Other · Disposed Not disclosed · Balance Not disclosed F1: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2: Currently exercisable. F4: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. |
| Senior Secured Convertible NoteSEC Table II · derivative / convertible security · Conversion / exercise price $0.15 · Expires 2028-08-17 | IndirectBy Pura Vida Pro Special Opportunity Master Fund, LTD. | Not disclosed |
Reported balance
After 2021-08-17 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-08-17 · Other · Disposed Not disclosed · Balance Not disclosed F1: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2: Currently exercisable. F4: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. |
| Senior Secured Convertible NoteSEC Table II · derivative / convertible security · Conversion / exercise price $0.34 · Expires 2028-08-17 | IndirectBy Pura Vida Pro Special Opportunity Master Fund, LTD. | Not disclosed |
Reported balance
After 2021-08-17 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-08-17 · Other · Disposed Not disclosed · Balance Not disclosed F1: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2: Currently exercisable. F4: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. |
| Senior Secured Convertible NoteSEC Table II · derivative / convertible security · Conversion / exercise price $0.28 · Expires 2028-08-17 | IndirectBy Pura Vida Pro Special Opportunity Master Fund, LTD. | Not disclosed |
Reported balance
After 2021-08-17 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-08-17 · Other · Disposed Not disclosed · Balance Not disclosed F1: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2: Currently exercisable. F4: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $3.72 · Expires 2022-05-22 | IndirectBy Pura Vida Master Fund, LTD. | 234,753 |
Reported balance
After 2021-08-17 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-08-17 · Other · Disposed 435,971 · Balance 234,753 F1: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2: Currently exercisable. F4: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $4.29 · Expires 2022-05-22 | IndirectBy Pura Vida Master Fund, LTD. | 67,818 |
Reported balance
After 2021-08-17 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-08-17 · Other · Disposed 125,947 · Balance 67,818 F1: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2: Currently exercisable. F4: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $3.16 · Expires 2022-07-12 | IndirectBy Pura Vida Master Fund, LTD. | 69,074 |
Reported balance
After 2021-08-17 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-08-17 · Other · Disposed 128,279 · Balance 69,074 F1: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2: Currently exercisable. F4: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $3.65 · Expires 2022-07-12 | IndirectBy Pura Vida Master Fund, LTD. | 19,955 |
Reported balance
After 2021-08-17 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2021-08-17 · Other · Disposed 37,058 · Balance 19,955 F1: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2: Currently exercisable. F4: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.01 · Expires 2022-11-27 | IndirectBy Pura Vida Master Fund, LTD. | 86,322 |
Reported balance
After 2021-08-17 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2021-08-17 · Other · Disposed 160,311 · Balance 86,322 F1: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2: Currently exercisable. F4: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.17 · Expires 2022-11-27 | IndirectBy Pura Vida Master Fund, LTD. | 24,938 |
Reported balance
After 2021-08-17 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2021-08-17 · Other · Disposed 46,313 · Balance 24,938 F1: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2: Currently exercisable. F4: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.15 · Expires 2025-03-27 | IndirectBy Pura Vida Master Fund, LTD. | 4,349,248 |
Reported balance
After 2021-08-17 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2021-08-17 · Other · Disposed 8,077,175 · Balance 4,349,248 F1: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2: Currently exercisable. F4: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $3.72 · Expires 2022-05-22 | IndirectBy Pura Vida Pro Special Opportunity Master Fund, LTD. | 74,132 |
Reported balance
After 2021-08-17 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2021-08-17 · Other · Disposed 137,675 · Balance 74,132 F1: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2: Currently exercisable. F4: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $4.29 · Expires 2022-05-22 | IndirectBy Pura Vida Pro Special Opportunity Master Fund, LTD. | 21,416 |
Reported balance
After 2021-08-17 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2021-08-17 · Other · Disposed 39,773 · Balance 21,416 F1: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2: Currently exercisable. F4: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $3.16 · Expires 2022-07-12 | IndirectBy Pura Vida Pro Special Opportunity Master Fund, LTD. | 21,813 |
Reported balance
After 2021-08-17 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2021-08-17 · Other · Disposed 40,509 · Balance 21,813 F1: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2: Currently exercisable. F4: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $3.65 · Expires 2022-07-12 | IndirectBy Pura Vida Pro Special Opportunity Master Fund, LTD. | 6,301 |
Reported balance
After 2021-08-17 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2021-08-17 · Other · Disposed 11,703 · Balance 6,301 F1: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2: Currently exercisable. F4: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.01 · Expires 2022-11-27 | IndirectBy Pura Vida Pro Special Opportunity Master Fund, LTD. | 27,259 |
Reported balance
After 2021-08-17 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2021-08-17 · Other · Disposed 50,625 · Balance 27,259 F1: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2: Currently exercisable. F4: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.17 · Expires 2022-11-27 | IndirectBy Pura Vida Pro Special Opportunity Master Fund, LTD. | 7,875 |
Reported balance
After 2021-08-17 transaction · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · 2021-08-17 · Other · Disposed 14,625 · Balance 7,875 F1: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2: Currently exercisable. F4: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.15 · Expires 2025-03-27 | IndirectBy Pura Vida Pro Special Opportunity Master Fund, LTD. | 1,373,447 |
Reported balance
After 2021-08-17 transaction · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · 2021-08-17 · Other · Disposed 2,550,687 · Balance 1,373,447 F1: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2: Currently exercisable. F4: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities.
F2: Currently exercisable.
F3: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment.
F4: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP.
F5: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein.
STRYVE FOODS, INC.
Report date September 15, 2021 · Filed September 17, 2021
Jointly reported with Kamen Efrem
Section 16 reporting ended · disclosed 2021-09-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 450,000 |
Reported balance
After 2021-09-15 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-09-15 · Sale · Disposed 800,000 · Balance 450,000 F3: On September 15, 2021 (the "Effective Date"), the Issuer, Pura Vida and the Advisory Clients entered into that certain Share Purchase Agreement, pursuant to which the parties effected as of the Effective Date a simultaneous exchange of an aggregate of 800,000 shares of Common Stock held by the Advisory Clients for the Prepaid Warrants of the Issuer to purchase an aggregate of 800,000 shares of Common Stock. F1: The shares of the Issuer's Class A Common Stock (the "Common Stock") reported herein were directly owned by certain private investment vehicles and accounts managed or sub-advised by Pura Vida Investments, LLC ("Pura Vida" and such private investment vehicles and accounts, the "Advisory Clients"). F6: The reported securities may be deemed beneficially owned by Pura Vida as investment manager or sub-adviser of the Advisory Clients. The reported securities may also be deemed beneficially owned by Efrem Kamen as the principal of Pura Vida. Each of Pura Vida and Mr. Kamen (the "Reporting Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Prepaid Common Stock Purchase Warrant (right to buy)SEC Table II · derivative / convertible security | IndirectSee footnote | 800,000 |
Reported balance
After 2021-09-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-09-15 · Purchase · Acquired 800,000 · Balance 800,000 F5: Subject to the Beneficial Ownership Limitation, each Prepaid Warrant may be exercised at the option of the holder for no additional consideration. The Prepaid Warrants have no expiration date. F3: On September 15, 2021 (the "Effective Date"), the Issuer, Pura Vida and the Advisory Clients entered into that certain Share Purchase Agreement, pursuant to which the parties effected as of the Effective Date a simultaneous exchange of an aggregate of 800,000 shares of Common Stock held by the Advisory Clients for the Prepaid Warrants of the Issuer to purchase an aggregate of 800,000 shares of Common Stock. F4: The terms of each Prepaid Warrant provide that the holder of such Prepaid Warrant does not have the right to exercise, and the Issuer shall not effect any exercise of, any portion of such Prepaid Warrant to the extent that, after giving effect to the issuance of Common Stock after such exercise, the holder (together with such holder's affiliates, and any persons acting as a group together with such holder or affiliates) would beneficially own in excess of 9.99% of the shares of the Common Stock then issued and outstanding, which percentage may be changed at the holder's election upon 61 days' notice to the Issuer (the "Beneficial Ownership Limitation"). F2: The Prepaid Common Stock Purchase Warrants (the "Prepaid Warrants") reported herein are directly owned by the Advisory Clients. F6: The reported securities may be deemed beneficially owned by Pura Vida as investment manager or sub-adviser of the Advisory Clients. The reported securities may also be deemed beneficially owned by Efrem Kamen as the principal of Pura Vida. Each of Pura Vida and Mr. Kamen (the "Reporting Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of the Issuer's Class A Common Stock (the "Common Stock") reported herein were directly owned by certain private investment vehicles and accounts managed or sub-advised by Pura Vida Investments, LLC ("Pura Vida" and such private investment vehicles and accounts, the "Advisory Clients").
F2: The Prepaid Common Stock Purchase Warrants (the "Prepaid Warrants") reported herein are directly owned by the Advisory Clients.
F3: On September 15, 2021 (the "Effective Date"), the Issuer, Pura Vida and the Advisory Clients entered into that certain Share Purchase Agreement, pursuant to which the parties effected as of the Effective Date a simultaneous exchange of an aggregate of 800,000 shares of Common Stock held by the Advisory Clients for the Prepaid Warrants of the Issuer to purchase an aggregate of 800,000 shares of Common Stock.
F4: The terms of each Prepaid Warrant provide that the holder of such Prepaid Warrant does not have the right to exercise, and the Issuer shall not effect any exercise of, any portion of such Prepaid Warrant to the extent that, after giving effect to the issuance of Common Stock after such exercise, the holder (together with such holder's affiliates, and any persons acting as a group together with such holder or affiliates) would beneficially own in excess of 9.99% of the shares of the Common Stock then issued and outstanding, which percentage may be changed at the holder's election upon 61 days' notice to the Issuer (the "Beneficial Ownership Limitation").
F5: Subject to the Beneficial Ownership Limitation, each Prepaid Warrant may be exercised at the option of the holder for no additional consideration. The Prepaid Warrants have no expiration date.
F6: The reported securities may be deemed beneficially owned by Pura Vida as investment manager or sub-adviser of the Advisory Clients. The reported securities may also be deemed beneficially owned by Efrem Kamen as the principal of Pura Vida. Each of Pura Vida and Mr. Kamen (the "Reporting Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 05, 2023 Filed Apr 7, 2023 21:12 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock | 663,000 | $0.30 | $200,027.10 |
DisclosureSEC source: 0001209191-23-023828 · doc4.xml · nonDerivative · entry 1 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Pura Vida Master Fund, Ltd. Disclosed balance after: 8,090,202 F1 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd., Pura Vida X Fund LP, and Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts" and collectively, the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F2 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:54 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | OtherCommon Stock | 3,890,111 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-017430 · doc4.xml · nonDerivative · entry 1 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Managed Accounts. Disclosed balance after: 4,589,571 F1 · kind: As of March 6, 2023, the Reporting Persons no longer have voting and dispositive power for certain Managed Accounts and therefore such shares are no longer deemed beneficially owned by the Reporting Persons. F2 · price: Not applicable. F3 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd., Pura Vida X Fund LP, and Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust") and certain separately managed accounts (the "Managed Accounts" and collectively, the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F4 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| March 06, 2023 Filed Apr 18, 2023 22:49 UTC Amendment | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | OtherWarrant to purchase common stock · Derivative | 440,964 | Not disclosed Strike: $1.53 | Not disclosed |
DisclosureSEC source: 0001209191-23-024720 · doc4a.xml · derivative · entry 5 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By the Managed Accounts. Disclosed balance after: 517,245 Underlying: Common Stock · 440,964 shares Expires 2027-04-19 F5 · kind: As of March 6, 2023, the Reporting Persons no longer have voting and dispositive power for certain Managed Accounts and therefore the warrants and the underlying common stock are no longer deemed beneficially owned by the Reporting Persons. F2 · price: Not applicable. F6 · ownership.nature: See footnotes 3 and 4. Read SEC document |
| March 06, 2023 Filed Apr 18, 2023 22:49 UTC Amendment | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | OtherCommon Stock | 3,890,111 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-024720 · doc4a.xml · nonDerivative · entry 1 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By the Managed Accounts. Disclosed balance after: 4,589,571 F1 · kind: As of March 6, 2023, the Reporting Persons no longer have voting and dispositive power for certain Managed Accounts and therefore such shares are no longer deemed beneficially owned by the Reporting Persons. F2 · price: Not applicable. F3 · ownership.nature: Securities reported herein are owned by Pura Vida Master Fund, Ltd., Pura Vida X Fund LP, and Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust") and certain separately managed accounts (the "Managed Accounts" and collectively, the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F4 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 23:48 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | SaleCommon Stock | 40,464 | $1.03 | $41,552.48 |
DisclosureSEC source: 0001209191-22-039692 · doc4.xml · nonDerivative · entry 4 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Managed Accounts. Disclosed balance after: 8,479,682 F1 · shares: Aggregate number of shares sold on the same date at difference prices. F5 · price: Represents the weighted-average sales price. The shares were sold in multiple transactions at prices ranging from $1.02 to $1.0475, inclusive, per share. Full information regarding the number of shares sold at each price shall be provided to the Staff, Issuer or any security holder, upon request. F3 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund") and certain separately managed accounts (the "Managed Accounts," and together with the Pura Vida Master Fund, collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F4 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 23:48 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | SaleCommon Stock | 12,517 | $1.05 | $13,160.37 |
DisclosureSEC source: 0001209191-22-039692 · doc4.xml · nonDerivative · entry 3 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Managed Accounts. Disclosed balance after: 8,520,146 F1 · shares: Aggregate number of shares sold on the same date at difference prices. F2 · price: Represents the weighted-average sales price. The shares were sold in multiple transactions at prices ranging from $1.04 to $1.09, inclusive, per share. Full information regarding the number of shares sold at each price shall be provided to the Securities and Exchange Commission staff (the "Staff), Issuer or any security holder, upon request. F3 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund") and certain separately managed accounts (the "Managed Accounts," and together with the Pura Vida Master Fund, collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F4 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 23:48 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | SaleCommon Stock | 35,441 | $1.03 | $36,394.36 |
DisclosureSEC source: 0001209191-22-039692 · doc4.xml · nonDerivative · entry 2 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida Master Fund, Ltd. Disclosed balance after: 7,427,202 F1 · shares: Aggregate number of shares sold on the same date at difference prices. F5 · price: Represents the weighted-average sales price. The shares were sold in multiple transactions at prices ranging from $1.02 to $1.0475, inclusive, per share. Full information regarding the number of shares sold at each price shall be provided to the Staff, Issuer or any security holder, upon request. F3 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund") and certain separately managed accounts (the "Managed Accounts," and together with the Pura Vida Master Fund, collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F4 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 23:48 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | SaleCommon Stock | 10,964 | $1.05 | $11,527.55 |
DisclosureSEC source: 0001209191-22-039692 · doc4.xml · nonDerivative · entry 1 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida Master Fund, Ltd. Disclosed balance after: 7,462,643 F1 · shares: Aggregate number of shares sold on the same date at difference prices. F2 · price: Represents the weighted-average sales price. The shares were sold in multiple transactions at prices ranging from $1.04 to $1.09, inclusive, per share. Full information regarding the number of shares sold at each price shall be provided to the Securities and Exchange Commission staff (the "Staff), Issuer or any security holder, upon request. F3 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund") and certain separately managed accounts (the "Managed Accounts," and together with the Pura Vida Master Fund, collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F4 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Apr 19, 2022 01:55 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseWarrant to purchase common stock · Derivative | 958,209 | Not disclosed Strike: $1.53 | Not disclosed |
DisclosureSEC source: 0001829126-22-008372 · ownership.xml · derivative · entry 12 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Managed Accounts Disclosed balance after: 958,209 Underlying: Common Stock · 958,209 shares Expires 2027-04-19 F1 · price: Each share of common stock was purchased together with one warrant to purchase 0.5 shares of common stock at a combined offering price of $1.3325. F4 · derivative.exercise_date: The Warrants are subject to an ownership blocker provision that prevents the holder from exercising the Warrants if it would beneficially hold more than 19.99% of the common stock following such exercise. F2 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Apr 19, 2022 01:55 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseWarrant to purchase common stock · Derivative | 690,719 | Not disclosed Strike: $1.53 | Not disclosed |
DisclosureSEC source: 0001829126-22-008372 · ownership.xml · derivative · entry 11 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Retirement Trust Disclosed balance after: 690,719 Underlying: Common Stock · 690,719 shares Expires 2027-04-19 F1 · price: Each share of common stock was purchased together with one warrant to purchase 0.5 shares of common stock at a combined offering price of $1.3325. F4 · derivative.exercise_date: The Warrants are subject to an ownership blocker provision that prevents the holder from exercising the Warrants if it would beneficially hold more than 19.99% of the common stock following such exercise. F2 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Apr 19, 2022 01:55 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseWarrant to purchase common stock · Derivative | 383,976 | Not disclosed Strike: $1.53 | Not disclosed |
DisclosureSEC source: 0001829126-22-008372 · ownership.xml · derivative · entry 10 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida X Fund LP Disclosed balance after: 383,976 Underlying: Common Stock · 383,976 shares Expires 2027-04-19 F1 · price: Each share of common stock was purchased together with one warrant to purchase 0.5 shares of common stock at a combined offering price of $1.3325. F4 · derivative.exercise_date: The Warrants are subject to an ownership blocker provision that prevents the holder from exercising the Warrants if it would beneficially hold more than 19.99% of the common stock following such exercise. F2 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Apr 19, 2022 01:55 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseWarrant to purchase common stock · Derivative | 832,949 | Not disclosed Strike: $1.53 | Not disclosed |
DisclosureSEC source: 0001829126-22-008372 · ownership.xml · derivative · entry 9 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida Master Fund, Ltd. Disclosed balance after: 832,949 Underlying: Common Stock · 832,949 shares Expires 2027-04-19 F1 · price: Each share of common stock was purchased together with one warrant to purchase 0.5 shares of common stock at a combined offering price of $1.3325. F4 · derivative.exercise_date: The Warrants are subject to an ownership blocker provision that prevents the holder from exercising the Warrants if it would beneficially hold more than 19.99% of the common stock following such exercise. F2 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Apr 19, 2022 01:55 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock | 1,381,438 | $1.33 | $1,840,766.14 |
DisclosureSEC source: 0001829126-22-008372 · ownership.xml · nonDerivative · entry 8 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Retirement Trust Disclosed balance after: 1,381,438 F1 · shares: Each share of common stock was purchased together with one warrant to purchase 0.5 shares of common stock at a combined offering price of $1.3325. F2 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Apr 19, 2022 01:55 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock | 767,952 | $1.33 | $1,023,296.04 |
DisclosureSEC source: 0001829126-22-008372 · ownership.xml · nonDerivative · entry 7 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida X Fund LP Disclosed balance after: 767,952 F1 · shares: Each share of common stock was purchased together with one warrant to purchase 0.5 shares of common stock at a combined offering price of $1.3325. F2 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Apr 19, 2022 01:55 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock | 57,630 | $1.26 | $72,613.80 |
DisclosureSEC source: 0001829126-22-008372 · ownership.xml · nonDerivative · entry 6 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Managed Accounts Disclosed balance after: 8,532,663 F2 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Apr 19, 2022 01:55 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock | 19,210 | $1.23 | $23,570.67 |
DisclosureSEC source: 0001829126-22-008372 · ownership.xml · nonDerivative · entry 5 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Managed Accounts Disclosed balance after: 8,475,033 F2 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Apr 19, 2022 01:55 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock | 1,916,419 | $1.33 | $2,553,628.32 |
DisclosureSEC source: 0001829126-22-008372 · ownership.xml · nonDerivative · entry 4 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Managed Accounts Disclosed balance after: 8,455,823 F1 · shares: Each share of common stock was purchased together with one warrant to purchase 0.5 shares of common stock at a combined offering price of $1.3325. F2 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Apr 19, 2022 01:55 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock | 92,370 | $1.26 | $116,386.20 |
DisclosureSEC source: 0001829126-22-008372 · ownership.xml · nonDerivative · entry 3 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida Master Fund, Ltd. Disclosed balance after: 7,473,607 F2 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Apr 19, 2022 01:55 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock | 30,790 | $1.23 | $37,779.33 |
DisclosureSEC source: 0001829126-22-008372 · ownership.xml · nonDerivative · entry 2 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida Master Fund, Ltd. Disclosed balance after: 7,381,237 F2 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Apr 19, 2022 01:55 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock | 1,665,898 | $1.33 | $2,219,809.09 |
DisclosureSEC source: 0001829126-22-008372 · ownership.xml · nonDerivative · entry 1 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida Master Fund, Ltd. Disclosed balance after: 7,350,447 F1 · shares: Each share of common stock was purchased together with one warrant to purchase 0.5 shares of common stock at a combined offering price of $1.3325. F2 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Apr 29, 2022 20:33 UTC Amendment | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseWarrant to purchase common stock · Derivative | 958,209 | Not disclosed Strike: $1.53 | Not disclosed |
DisclosureSEC source: 0001829126-22-009190 · ownership.xml · derivative · entry 12 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Managed Accounts Disclosed balance after: 958,209 Underlying: Common Stock · 958,209 shares Expires 2027-04-19 F1 · price: Each share of common stock was purchased together with one warrant to purchase 0.5 shares of common stock at a combined offering price of $1.3325. F4 · derivative.exercise_date: The Warrants are subject to an ownership blocker provision that prevents the holder from exercising the Warrants if it would beneficially hold more than 19.99% of the common stock following such exercise. F2 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Apr 29, 2022 20:33 UTC Amendment | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseWarrant to purchase common stock · Derivative | 690,719 | Not disclosed Strike: $1.53 | Not disclosed |
DisclosureSEC source: 0001829126-22-009190 · ownership.xml · derivative · entry 11 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Retirement Trust Disclosed balance after: 690,719 Underlying: Common Stock · 690,719 shares Expires 2027-04-19 F1 · price: Each share of common stock was purchased together with one warrant to purchase 0.5 shares of common stock at a combined offering price of $1.3325. F4 · derivative.exercise_date: The Warrants are subject to an ownership blocker provision that prevents the holder from exercising the Warrants if it would beneficially hold more than 19.99% of the common stock following such exercise. F2 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Apr 29, 2022 20:33 UTC Amendment | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseWarrant to purchase common stock · Derivative | 383,976 | Not disclosed Strike: $1.53 | Not disclosed |
DisclosureSEC source: 0001829126-22-009190 · ownership.xml · derivative · entry 10 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida X Fund LP Disclosed balance after: 383,976 Underlying: Common Stock · 383,976 shares Expires 2027-04-19 F1 · price: Each share of common stock was purchased together with one warrant to purchase 0.5 shares of common stock at a combined offering price of $1.3325. F4 · derivative.exercise_date: The Warrants are subject to an ownership blocker provision that prevents the holder from exercising the Warrants if it would beneficially hold more than 19.99% of the common stock following such exercise. F2 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Apr 29, 2022 20:33 UTC Amendment | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseWarrant to purchase common stock · Derivative | 832,949 | Not disclosed Strike: $1.53 | Not disclosed |
DisclosureSEC source: 0001829126-22-009190 · ownership.xml · derivative · entry 9 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida Master Fund, Ltd. Disclosed balance after: 832,949 Underlying: Common Stock · 832,949 shares Expires 2027-04-19 F1 · price: Each share of common stock was purchased together with one warrant to purchase 0.5 shares of common stock at a combined offering price of $1.3325. F4 · derivative.exercise_date: The Warrants are subject to an ownership blocker provision that prevents the holder from exercising the Warrants if it would beneficially hold more than 19.99% of the common stock following such exercise. F2 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Apr 29, 2022 20:33 UTC Amendment | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock | 1,381,438 | $1.33 | $1,840,766.14 |
DisclosureSEC source: 0001829126-22-009190 · ownership.xml · nonDerivative · entry 8 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Retirement Trust Disclosed balance after: 1,381,438 F1 · shares: Each share of common stock was purchased together with one warrant to purchase 0.5 shares of common stock at a combined offering price of $1.3325. F2 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Apr 29, 2022 20:33 UTC Amendment | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock | 767,952 | $1.33 | $1,023,296.04 |
DisclosureSEC source: 0001829126-22-009190 · ownership.xml · nonDerivative · entry 7 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida X Fund LP Disclosed balance after: 767,952 F1 · shares: Each share of common stock was purchased together with one warrant to purchase 0.5 shares of common stock at a combined offering price of $1.3325. F2 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Apr 29, 2022 20:33 UTC Amendment | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock | 57,630 | $1.26 | $72,613.80 |
DisclosureSEC source: 0001829126-22-009190 · ownership.xml · nonDerivative · entry 6 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Managed Accounts Disclosed balance after: 8,532,663 F2 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Apr 29, 2022 20:33 UTC Amendment | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock | 19,210 | $1.23 | $23,570.67 |
DisclosureSEC source: 0001829126-22-009190 · ownership.xml · nonDerivative · entry 5 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Managed Accounts Disclosed balance after: 8,475,033 F2 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Apr 29, 2022 20:33 UTC Amendment | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock | 1,916,419 | $1.33 | $2,553,628.32 |
DisclosureSEC source: 0001829126-22-009190 · ownership.xml · nonDerivative · entry 4 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Managed Accounts Disclosed balance after: 8,455,823 F1 · shares: Each share of common stock was purchased together with one warrant to purchase 0.5 shares of common stock at a combined offering price of $1.3325. F2 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Apr 29, 2022 20:33 UTC Amendment | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock | 92,370 | $1.26 | $116,386.20 |
DisclosureSEC source: 0001829126-22-009190 · ownership.xml · nonDerivative · entry 3 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida Master Fund, Ltd. Disclosed balance after: 7,473,607 F2 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Apr 29, 2022 20:33 UTC Amendment | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock | 30,790 | $1.23 | $37,779.33 |
DisclosureSEC source: 0001829126-22-009190 · ownership.xml · nonDerivative · entry 2 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida Master Fund, Ltd. Disclosed balance after: 7,381,237 F2 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Apr 29, 2022 20:33 UTC Amendment | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock | 1,665,898 | $1.33 | $2,219,809.09 |
DisclosureSEC source: 0001829126-22-009190 · ownership.xml · nonDerivative · entry 1 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida Master Fund, Ltd. Disclosed balance after: 7,350,447 F1 · shares: Each share of common stock was purchased together with one warrant to purchase 0.5 shares of common stock at a combined offering price of $1.3325. F2 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F3 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Jun 28, 2022 23:46 UTC Amendment | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock | 57,630 | $1.26 | $72,613.80 |
DisclosureSEC source: 0001209191-22-039690 · doc4a.xml · nonDerivative · entry 4 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Managed Accounts. Disclosed balance after: 8,532,663 F1 · shares: Aggregate number of shares purchased on the same date at difference prices. F5 · price: Represents the weighted-average purchase price. The shares were purchased in multiple transactions at prices ranging from $1.235 to $1.305, inclusive, per share. Full information regarding the number of shares purchased at each price shall be provided to the Staff, Issuer or any security holder, upon request. F3 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund") and certain separately managed accounts (the "Managed Accounts," and together with the Pura Vida Master Fund, collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F4 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Jun 28, 2022 23:46 UTC Amendment | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock | 19,210 | $1.23 | $23,570.67 |
DisclosureSEC source: 0001209191-22-039690 · doc4a.xml · nonDerivative · entry 3 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Managed Accounts. Disclosed balance after: 8,475,033 F1 · shares: Aggregate number of shares purchased on the same date at difference prices. F2 · price: Represents the weighted-average purchase price. The shares were purchased in multiple transactions at prices ranging from $1.19 to $1.27, inclusive, per share. Full information regarding the number of shares purchased at each price shall be provided to the Securities and Exchange Commission staff (the "Staff"), Issuer or any security holder, upon request. F3 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund") and certain separately managed accounts (the "Managed Accounts," and together with the Pura Vida Master Fund, collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F4 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Jun 28, 2022 23:46 UTC Amendment | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock | 92,370 | $1.26 | $116,386.20 |
DisclosureSEC source: 0001209191-22-039690 · doc4a.xml · nonDerivative · entry 2 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida Master Fund, Ltd. Disclosed balance after: 7,473,607 F1 · shares: Aggregate number of shares purchased on the same date at difference prices. F5 · price: Represents the weighted-average purchase price. The shares were purchased in multiple transactions at prices ranging from $1.235 to $1.305, inclusive, per share. Full information regarding the number of shares purchased at each price shall be provided to the Staff, Issuer or any security holder, upon request. F3 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund") and certain separately managed accounts (the "Managed Accounts," and together with the Pura Vida Master Fund, collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F4 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| April 14, 2022 Filed Jun 28, 2022 23:46 UTC Amendment | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock | 30,790 | $1.23 | $37,779.33 |
DisclosureSEC source: 0001209191-22-039690 · doc4a.xml · nonDerivative · entry 1 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida Master Fund, Ltd. Disclosed balance after: 7,381,237 F1 · shares: Aggregate number of shares purchased on the same date at difference prices. F2 · price: Represents the weighted-average purchase price. The shares were purchased in multiple transactions at prices ranging from $1.19 to $1.27, inclusive, per share. Full information regarding the number of shares purchased at each price shall be provided to the Securities and Exchange Commission staff (the "Staff"), Issuer or any security holder, upon request. F3 · ownership.nature: Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund") and certain separately managed accounts (the "Managed Accounts," and together with the Pura Vida Master Fund, collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. F4 · ownership.nature: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:09 UTC | STRYVE FOODS, INC. SNAX · Entity 73502 | PurchasePrepaid Common Stock Purchase Warrant (right to buy) · Derivative | 800,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-116910 · tm2127858-1_4.xml · derivative · entry 2 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 800,000 Underlying: Class A Common Stock · 800,000 shares Expires not disclosed F5 · derivative.exercise_price: Subject to the Beneficial Ownership Limitation, each Prepaid Warrant may be exercised at the option of the holder for no additional consideration. The Prepaid Warrants have no expiration date. F3 · kind: On September 15, 2021 (the "Effective Date"), the Issuer, Pura Vida and the Advisory Clients entered into that certain Share Purchase Agreement, pursuant to which the parties effected as of the Effective Date a simultaneous exchange of an aggregate of 800,000 shares of Common Stock held by the Advisory Clients for the Prepaid Warrants of the Issuer to purchase an aggregate of 800,000 shares of Common Stock. F3 · price: On September 15, 2021 (the "Effective Date"), the Issuer, Pura Vida and the Advisory Clients entered into that certain Share Purchase Agreement, pursuant to which the parties effected as of the Effective Date a simultaneous exchange of an aggregate of 800,000 shares of Common Stock held by the Advisory Clients for the Prepaid Warrants of the Issuer to purchase an aggregate of 800,000 shares of Common Stock. F4 · derivative.exercise_date: The terms of each Prepaid Warrant provide that the holder of such Prepaid Warrant does not have the right to exercise, and the Issuer shall not effect any exercise of, any portion of such Prepaid Warrant to the extent that, after giving effect to the issuance of Common Stock after such exercise, the holder (together with such holder's affiliates, and any persons acting as a group together with such holder or affiliates) would beneficially own in excess of 9.99% of the shares of the Common Stock then issued and outstanding, which percentage may be changed at the holder's election upon 61 days' notice to the Issuer (the "Beneficial Ownership Limitation"). F5 · derivative.exercise_date: Subject to the Beneficial Ownership Limitation, each Prepaid Warrant may be exercised at the option of the holder for no additional consideration. The Prepaid Warrants have no expiration date. F5 · derivative.expiration_date: Subject to the Beneficial Ownership Limitation, each Prepaid Warrant may be exercised at the option of the holder for no additional consideration. The Prepaid Warrants have no expiration date. F2 · ownership.nature: The Prepaid Common Stock Purchase Warrants (the "Prepaid Warrants") reported herein are directly owned by the Advisory Clients. F6 · ownership.nature: The reported securities may be deemed beneficially owned by Pura Vida as investment manager or sub-adviser of the Advisory Clients. The reported securities may also be deemed beneficially owned by Efrem Kamen as the principal of Pura Vida. Each of Pura Vida and Mr. Kamen (the "Reporting Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:09 UTC | STRYVE FOODS, INC. SNAX · Entity 73502 | SaleClass A Common Stock | 800,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-116910 · tm2127858-1_4.xml · nonDerivative · entry 1 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 450,000 F3 · kind: On September 15, 2021 (the "Effective Date"), the Issuer, Pura Vida and the Advisory Clients entered into that certain Share Purchase Agreement, pursuant to which the parties effected as of the Effective Date a simultaneous exchange of an aggregate of 800,000 shares of Common Stock held by the Advisory Clients for the Prepaid Warrants of the Issuer to purchase an aggregate of 800,000 shares of Common Stock. F3 · price: On September 15, 2021 (the "Effective Date"), the Issuer, Pura Vida and the Advisory Clients entered into that certain Share Purchase Agreement, pursuant to which the parties effected as of the Effective Date a simultaneous exchange of an aggregate of 800,000 shares of Common Stock held by the Advisory Clients for the Prepaid Warrants of the Issuer to purchase an aggregate of 800,000 shares of Common Stock. F3 · acquired: On September 15, 2021 (the "Effective Date"), the Issuer, Pura Vida and the Advisory Clients entered into that certain Share Purchase Agreement, pursuant to which the parties effected as of the Effective Date a simultaneous exchange of an aggregate of 800,000 shares of Common Stock held by the Advisory Clients for the Prepaid Warrants of the Issuer to purchase an aggregate of 800,000 shares of Common Stock. F1 · ownership.nature: The shares of the Issuer's Class A Common Stock (the "Common Stock") reported herein were directly owned by certain private investment vehicles and accounts managed or sub-advised by Pura Vida Investments, LLC ("Pura Vida" and such private investment vehicles and accounts, the "Advisory Clients"). F6 · ownership.nature: The reported securities may be deemed beneficially owned by Pura Vida as investment manager or sub-adviser of the Advisory Clients. The reported securities may also be deemed beneficially owned by Efrem Kamen as the principal of Pura Vida. Each of Pura Vida and Mr. Kamen (the "Reporting Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| August 17, 2021 Filed Apr 29, 2022 20:45 UTC | MedMen Enterprises, Inc. MMNFF · Entity 94628 | OtherWarrant · Derivative | 2,550,687 | Not disclosed Strike: $0.15 | Not disclosed |
DisclosureSEC source: 0001209191-22-026285 · doc4.xml · derivative · entry 22 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Pura Vida Master Fund, LTD · CIK 0001912371 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida Pro Special Opportunity Master Fund, LTD. Disclosed balance after: 1,373,447 Underlying: Class B Subordinate Voting Shares · 3,924,133 shares Expires 2025-03-27 F1 · kind: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3 · price: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2 · derivative.exercise_date: Currently exercisable. F4 · ownership.nature: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5 · ownership.nature: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. Read SEC document |
| August 17, 2021 Filed Apr 29, 2022 20:45 UTC | MedMen Enterprises, Inc. MMNFF · Entity 94628 | OtherWarrant · Derivative | 14,625 | Not disclosed Strike: $1.17 | Not disclosed |
DisclosureSEC source: 0001209191-22-026285 · doc4.xml · derivative · entry 21 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Pura Vida Master Fund, LTD · CIK 0001912371 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida Pro Special Opportunity Master Fund, LTD. Disclosed balance after: 7,875 Underlying: Class B Subordinate Voting Shares · 22,500 shares Expires 2022-11-27 F1 · kind: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3 · price: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2 · derivative.exercise_date: Currently exercisable. F4 · ownership.nature: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5 · ownership.nature: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. Read SEC document |
| August 17, 2021 Filed Apr 29, 2022 20:45 UTC | MedMen Enterprises, Inc. MMNFF · Entity 94628 | OtherWarrant · Derivative | 50,625 | Not disclosed Strike: $1.01 | Not disclosed |
DisclosureSEC source: 0001209191-22-026285 · doc4.xml · derivative · entry 20 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Pura Vida Master Fund, LTD · CIK 0001912371 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida Pro Special Opportunity Master Fund, LTD. Disclosed balance after: 27,259 Underlying: Class B Subordinate Voting Shares · 77,884 shares Expires 2022-11-27 F1 · kind: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3 · price: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2 · derivative.exercise_date: Currently exercisable. F4 · ownership.nature: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5 · ownership.nature: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. Read SEC document |
| August 17, 2021 Filed Apr 29, 2022 20:45 UTC | MedMen Enterprises, Inc. MMNFF · Entity 94628 | OtherWarrant · Derivative | 11,703 | Not disclosed Strike: $3.65 | Not disclosed |
DisclosureSEC source: 0001209191-22-026285 · doc4.xml · derivative · entry 19 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Pura Vida Master Fund, LTD · CIK 0001912371 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida Pro Special Opportunity Master Fund, LTD. Disclosed balance after: 6,301 Underlying: Class B Subordinate Voting Shares · 18,004 shares Expires 2022-07-12 F1 · kind: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3 · price: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2 · derivative.exercise_date: Currently exercisable. F4 · ownership.nature: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5 · ownership.nature: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. Read SEC document |
| August 17, 2021 Filed Apr 29, 2022 20:45 UTC | MedMen Enterprises, Inc. MMNFF · Entity 94628 | OtherWarrant · Derivative | 40,509 | Not disclosed Strike: $3.16 | Not disclosed |
DisclosureSEC source: 0001209191-22-026285 · doc4.xml · derivative · entry 18 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Pura Vida Master Fund, LTD · CIK 0001912371 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida Pro Special Opportunity Master Fund, LTD. Disclosed balance after: 21,813 Underlying: Class B Subordinate Voting Shares · 62,322 shares Expires 2022-07-12 F1 · kind: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3 · price: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2 · derivative.exercise_date: Currently exercisable. F4 · ownership.nature: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5 · ownership.nature: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. Read SEC document |
| August 17, 2021 Filed Apr 29, 2022 20:45 UTC | MedMen Enterprises, Inc. MMNFF · Entity 94628 | OtherWarrant · Derivative | 39,773 | Not disclosed Strike: $4.29 | Not disclosed |
DisclosureSEC source: 0001209191-22-026285 · doc4.xml · derivative · entry 17 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Pura Vida Master Fund, LTD · CIK 0001912371 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida Pro Special Opportunity Master Fund, LTD. Disclosed balance after: 21,416 Underlying: Class B Subordinate Voting Shares · 61,189 shares Expires 2022-05-22 F1 · kind: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3 · price: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2 · derivative.exercise_date: Currently exercisable. F4 · ownership.nature: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5 · ownership.nature: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. Read SEC document |
| August 17, 2021 Filed Apr 29, 2022 20:45 UTC | MedMen Enterprises, Inc. MMNFF · Entity 94628 | OtherWarrant · Derivative | 137,675 | Not disclosed Strike: $3.72 | Not disclosed |
DisclosureSEC source: 0001209191-22-026285 · doc4.xml · derivative · entry 16 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Pura Vida Master Fund, LTD · CIK 0001912371 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida Pro Special Opportunity Master Fund, LTD. Disclosed balance after: 74,132 Underlying: Class B Subordinate Voting Shares · 211,807 shares Expires 2022-05-22 F1 · kind: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3 · price: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2 · derivative.exercise_date: Currently exercisable. F4 · ownership.nature: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5 · ownership.nature: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. Read SEC document |
| August 17, 2021 Filed Apr 29, 2022 20:45 UTC | MedMen Enterprises, Inc. MMNFF · Entity 94628 | OtherWarrant · Derivative | 8,077,175 | Not disclosed Strike: $0.15 | Not disclosed |
DisclosureSEC source: 0001209191-22-026285 · doc4.xml · derivative · entry 15 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Pura Vida Master Fund, LTD · CIK 0001912371 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida Master Fund, LTD. Disclosed balance after: 4,349,248 Underlying: Class B Subordinate Voting Shares · 12,426,422 shares Expires 2025-03-27 F1 · kind: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3 · price: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2 · derivative.exercise_date: Currently exercisable. F4 · ownership.nature: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5 · ownership.nature: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. Read SEC document |
| August 17, 2021 Filed Apr 29, 2022 20:45 UTC | MedMen Enterprises, Inc. MMNFF · Entity 94628 | OtherWarrant · Derivative | 46,313 | Not disclosed Strike: $1.17 | Not disclosed |
DisclosureSEC source: 0001209191-22-026285 · doc4.xml · derivative · entry 14 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Pura Vida Master Fund, LTD · CIK 0001912371 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida Master Fund, LTD. Disclosed balance after: 24,938 Underlying: Class B Subordinate Voting Shares · 71,250 shares Expires 2022-11-27 F1 · kind: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3 · price: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2 · derivative.exercise_date: Currently exercisable. F4 · ownership.nature: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5 · ownership.nature: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. Read SEC document |
| August 17, 2021 Filed Apr 29, 2022 20:45 UTC | MedMen Enterprises, Inc. MMNFF · Entity 94628 | OtherWarrant · Derivative | 160,311 | Not disclosed Strike: $1.01 | Not disclosed |
DisclosureSEC source: 0001209191-22-026285 · doc4.xml · derivative · entry 13 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Pura Vida Master Fund, LTD · CIK 0001912371 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida Master Fund, LTD. Disclosed balance after: 86,322 Underlying: Class B Subordinate Voting Shares · 246,633 shares Expires 2022-11-27 F1 · kind: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3 · price: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2 · derivative.exercise_date: Currently exercisable. F4 · ownership.nature: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5 · ownership.nature: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. Read SEC document |
| August 17, 2021 Filed Apr 29, 2022 20:45 UTC | MedMen Enterprises, Inc. MMNFF · Entity 94628 | OtherWarrant · Derivative | 37,058 | Not disclosed Strike: $3.65 | Not disclosed |
DisclosureSEC source: 0001209191-22-026285 · doc4.xml · derivative · entry 12 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Pura Vida Master Fund, LTD · CIK 0001912371 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida Master Fund, LTD. Disclosed balance after: 19,955 Underlying: Class B Subordinate Voting Shares · 57,013 shares Expires 2022-07-12 F1 · kind: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3 · price: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2 · derivative.exercise_date: Currently exercisable. F4 · ownership.nature: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5 · ownership.nature: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. Read SEC document |
| August 17, 2021 Filed Apr 29, 2022 20:45 UTC | MedMen Enterprises, Inc. MMNFF · Entity 94628 | OtherWarrant · Derivative | 128,279 | Not disclosed Strike: $3.16 | Not disclosed |
DisclosureSEC source: 0001209191-22-026285 · doc4.xml · derivative · entry 11 PURA VIDA INVESTMENTS, LLC · CIK 0001590144 · 10% owner Pura Vida Master Fund, LTD · CIK 0001912371 · 10% owner Kamen Efrem · CIK 0001789193 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pura Vida Master Fund, LTD. Disclosed balance after: 69,074 Underlying: Class B Subordinate Voting Shares · 197,353 shares Expires 2022-07-12 F1 · kind: In connection with the disposition of the securities, the parties entered into a Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021, pursuant to which amended and restated senior secured convertible notes (the "Notes") and warrants (the "Warrants") were issued. The maturity date on the Notes was changed from April 23, 2022 to August 17, 2028. As a result of the disposition of the Notes and Warrants, the Reporting Persons no longer beneficially own more than 10% of the Issuer's securities. F3 · price: The Notes and Warrants reported on this Form 4 were sold for aggregate cash consideration of $6,251,483 plus an aggregate of 1,062,068 shares of common stock of Tilray, Inc., subject to adjustment. F2 · derivative.exercise_date: Currently exercisable. F4 · ownership.nature: The reporting persons (the "Reporting Persons") are Pura Vida Investments, LLC ("PVI"), Pura Vida Master Fund, LTD. (the "PV Master Fund"), and Efrem Kamen. PVI serves as the investment manager to the PV Master Fund. Pura Vida Pro, LLC ("PVP") serves as the investment manager to Pura Vida Pro Special Opportunity Master Fund, LTD. PVP is a relying adviser of PVI. Efrem Kamen serves as the managing member of both PVI and PVP. F5 · ownership.nature: This Form 4 shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the securities reported herein except to the extent of PVI's and Efrem Kamen's pecuniary interest, if any, therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.